Clinical Trial Update: A Phase I, Open-label Trial to Explore the Pharmacokinetics, Safety and Tolerability of TMC278 (Rilpivirine) 25 mg Once Daily Following a 2-week Period Receiving Efavirenz, in Healthy Male and Female Volunteers [Phase 1]

View source ↗

Summary

A Phase I open-label study assessing the pharmacokinetics, safety and tolerability of rilpivirine (TMC278) 25 mg daily after two weeks of efavirenz in healthy v…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• EFAVIRENZ (efavirenz)
• rilpivirine (rilpivirine)

Snippet

Sponsor: Tibotec, Inc | Conditions: HIV | Phase 1 | Status: COMPLETED